Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients
11 mai 2022 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”
09 mai 2022 08h30 HE
|
Dyadic International, Inc.
Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100,...
Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
28 avr. 2022 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform
13 avr. 2022 08h52 HE
|
Dyadic International, Inc.
India’s Department of Biotechnology, Government of India to support scale up and production of cGMP batches of SARS-CoV-2 antigenFunding earmarked to support Phase 1 and 2 clinical trials of Epygen’s...
Dyadic International to Present at Upcoming Scientific Medical Meetings
04 avr. 2022 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., April 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and...
Dyadic Reports 2021 Year End Results and Recent Company Progress
29 mars 2022 16h00 HE
|
Dyadic International, Inc.
New research, license and collaboration agreement with Janssen for the development and manufacture of therapeutic proteinsReceived NIIMBL coronavirus grant of $690,000 under the White House’s American...
Dyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022
15 mars 2022 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine
10 févr. 2022 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference
07 févr. 2022 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and...
Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process
20 janv. 2022 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...